Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock Position Trimmed by Mesirow Financial Investment Management Inc.

Mesirow Financial Investment Management Inc. trimmed its position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAYFree Report) by 17.7% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,536 shares of the company’s stock after selling 3,131 shares during the period. Mesirow Financial Investment Management Inc.’s holdings in Relay Therapeutics were worth $103,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in RLAY. EverSource Wealth Advisors LLC bought a new position in Relay Therapeutics in the 2nd quarter worth approximately $37,000. Allspring Global Investments Holdings LLC bought a new position in shares of Relay Therapeutics in the first quarter worth $79,000. Virtu Financial LLC acquired a new position in shares of Relay Therapeutics during the first quarter valued at $87,000. Values First Advisors Inc. bought a new stake in shares of Relay Therapeutics during the third quarter valued at about $75,000. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of Relay Therapeutics during the 1st quarter worth about $127,000. Institutional investors and hedge funds own 96.98% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Barclays lifted their price target on Relay Therapeutics from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, September 10th. HC Wainwright upped their price target on shares of Relay Therapeutics from $19.00 to $20.00 and gave the company a “buy” rating in a report on Friday, November 8th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Relay Therapeutics in a research note on Monday, September 16th. Oppenheimer lowered shares of Relay Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, September 10th. Finally, Jefferies Financial Group upgraded shares of Relay Therapeutics from a “hold” rating to a “buy” rating and lifted their price target for the stock from $10.60 to $16.00 in a research report on Tuesday, September 10th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, Relay Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $21.22.

View Our Latest Stock Analysis on RLAY

Insider Activity

In other Relay Therapeutics news, CFO Thomas Catinazzo sold 6,802 shares of the stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $6.06, for a total value of $41,220.12. Following the completion of the sale, the chief financial officer now owns 306,391 shares in the company, valued at $1,856,729.46. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.32% of the stock is owned by corporate insiders.

Relay Therapeutics Stock Performance

Shares of NASDAQ:RLAY opened at $5.81 on Thursday. The firm has a 50 day simple moving average of $6.76 and a 200 day simple moving average of $7.01. Relay Therapeutics, Inc. has a 52 week low of $5.60 and a 52 week high of $12.14.

Relay Therapeutics (NASDAQ:RLAYGet Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.14. The firm’s revenue for the quarter was down 100.0% compared to the same quarter last year. During the same period last year, the firm posted ($0.54) earnings per share. As a group, analysts expect that Relay Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Relay Therapeutics Company Profile

(Free Report)

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.

Recommended Stories

Want to see what other hedge funds are holding RLAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Relay Therapeutics, Inc. (NASDAQ:RLAYFree Report).

Institutional Ownership by Quarter for Relay Therapeutics (NASDAQ:RLAY)

Receive News & Ratings for Relay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.